depend long-term trajectori
last night deliv seri strateg updat industri confer
improv visibl near-term growth trend end
stronger-than expect note revenu million beat forecast
better consum growth due part stock order
novaseq instal base stand roughli line forecast driven
consist placement q/q continu see multi-year upgrad cycl ahead
novaseq note hiseq custom upgrad
new platform far provid guidanc modestli better
forecast revenu growth guid increas vs model
ep guid includ benefit tax reform dilut
invest helix came prior forecast
longer term need greater convict elast sequenc demand
power revenu growth drive price sequenc
novaseq launch earli tout architectur futur
high-throughput sequenc undeni perform characterist
view consum growth indic demand elast point
note full-year consum growth lowest track record
follow growth
challeng drive demand faster compani push price
compani embark genom time view sustain
consum growth critic long-term busi model valuat
ampl opportun ahead across research clinic consum market
thought ceo franci desouza good job highlight compani
progress build ecosystem new iseq launch show
progress toward decentr sequenc ampliseq partnership
thermo fisher show commit develop better workflow custom
rais price target better visibl near-term
trajectori also reiter equal weight rate thesi continu
look greater convict long-term growth order justifi valuat
quarterli annual ep usd
rais usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
equal weight leader next
gener sequenc market
project growth
posit fundament
impress compani abil transform
genom market believ sentiment well
reflect share
compani instal base grow higher
consum revenu contribut margin
leverag estim upsid case
reflect upsid ebitda billion
given pace innov cycl next
gener sequenc believ still
earli declar instrument choic
clinic use downsid case reflect
downsid ebitda million
margin return data
balanc sheet cash flow
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
last night deliv seri strateg updat industri confer
improv visibl near-term growth trend notabl end
stronger-than expect note revenu million beat forecast
driven better consum growth due part stock order million
illumina novaseq instal base stand roughli line forecast
driven consist placement q/q compani continu see multi-year
upgrad cycl ahead novaseq note hiseq custom
upgrad new platform far provid guidanc modestli better
forecast revenu growth guid increas vs model
ep guid includ benefit tax reform dilut
invest helix came prior forecast
longer term need greater convict elast sequenc demand
power revenu growth drive price sequenc novaseq
launch earli tout architectur futur high-
throughput sequenc undeni perform characterist view
consum growth indic demand elast point note full-year
consum growth lowest track record follow
growth challeng
drive demand faster compani push price compani embark
genom time view sustain consum growth
critic long-term busi model valuat ampl opportun
ahead across research clinic consum market thought ceo franci
desouza good job highlight compani progress build
sequenc ampliseq partnership thermo fisher show commit
develop better workflow custom reiter equal weight rate
thesi continu look greater convict long-term growth order
better visibl near-term growth rais price target
price target repres adj ebitda billion
continu valuat sensit especi context long-term growth
project prior price target repres ebitda million
term financi releas guidanc includ revenu
ep expect compani expect growth y/i
midpoint higher estim revenu growth
also higher base due revenu beat ep guid rang
prior estim includ anticip
benefit due tax reform ep dilut helix cfo ad describ
 benefit lower statutori tax rate partial off-set higher
intern tax go driver growth includ novaseq util
demand clinic translat custom well growth consum
also deliv preliminari result better expect
compani expect report revenu million higher estim
million repres y/i growth compani attribut beat
strength sale compani consum grew quarter
driven increas util high-throughput system novaseq
well better-than-expect nextseq perform
sequenc
consum quarter stock order one novaseq custom
said even exclud order novaseq consum still would grown
sequenti rel low base place around novaseq
quarter compani note flow cell catalyst demand
quarter microarray strong quarter driven continu demand
consum genom market compani disclos ep result await
detail compani earn call
present introduc iseq instrument expand
breadth lower-throughput end sequenc market view
instrument nice addit portfolio though addit growth
vs high-throughput platform compani describ iseq inexpens fast
easi use sequenc iseq util best-in-bre sequenc
synthesi sb chemistri coupl complementari metal-oxide-semiconductor
cmo detect technolog iseq target address market
potenti custom rang current owner new-to- custom iseq
gener million read greater per run run-tim rang
hour price per sampl rang addit
sequenc cost less instal custom less one hour
current take order iseq shipment expect begin
acceler follow manufactur scale
addit iseq launch announc partnership thermo fisher
allow compani commerci thermo fisher ion ampliseq
technolog research custom ceo franci desouza note break-out
session agreement stem mutual understand two
compani thermo fisher develop best-in-class amplicon technolog allow
effect captur dna rna small amount sampl thermo fisher
provid ion ampliseq technolog distribut directli
custom name ampliseq agreement preclud
thermo fisher sell ampliseq technolog current new sequenc
custom believ agreement commend show illumina
willing partner best-in-class product even mean partner
major competitor thermo fisher give compani new revenu growth
access sizabl instal base
novaseq placement high
expect flat sequenti total novaseq placement
exclud million order novaseq consum grew sequenti
though low base ceo desouza note introduct flow
cell import drive placement also continu confid
novaseq expand whole-genom sequenc market custom
either new upgrad compani desktop sequenc platform
compani still believ earli stage replac cycl
approxim high throughput custom adopt novaseq regard
futur desouza touch number on-going whole genom sequenc
initi exampl regeneron work sequenc genom
model forecast novaseq placement
averag consum pull-through follow expect drop-off
placement includ assum approxim
placement replac come hiseq custom possibl compani
could see cannib hiseq custom well given rel advantag
novaseq forecast million novaseq revenu year
launch compar million nextseq revenu million
hiseq revenu year launch estim
list prospect novaseq placement
market clearli excit prospect novaseq said continu
debat around capac constraint upper end sequenc market
face headwind high-throughput sequenc market
impact sale hiseq line sequenc manifest lower instrument
sale well lower consum pull-through hiseq
versu prior rang introduct novaseq offer cost
qualiti ease-of-us turnaround advantag custom compani believ
drive price point sequenc expand market said
launch inher differ prior launch given rel matur
compani custom note consum growth moder
follow growth growth year prior
new product launch import drive top line growth increas
sequenc demand analyz success last major new product cycl
hiseq nextseq introduct found strong
product launch begin carri compani
busi line grown modestli specif
competitor industri confer introduc hiseq nextseq
follow launch estim product contribut million
revenu place hiseq instrument million
nextseq system lead overal revenu growth momentum remain
strong leverag instal base higher consum growth
believ factor contribut signific interest launch
hiseq view game-chang whole-genom sequenc push price
point sequenc nextseq fill gap portfolio
first major product launch two year hiseq
hiseq nextseq meaning contributor overal revenu growth
sinc launch novaseq help improv visibl
specif estim hiseq nextseq product contribut
revenu growth balanc illumina
portfolio seen modest revenu growth
look portfolio similarli hiseq nextseq
workhors growth rate estim balanc illumina portfolio
miniseq miseq hiseq actual declin
illumina revenu contribut novaseq hiseq nextseq
continu wrestl right valuat recommend invest
compani clear market leader next-gener sequenc
fastest grow market life scienc tool technolog opinion matter
way diagnost market move genom expect play critic role
backbon innov addit compani invest thesi cater
well wide array investor base healthcar technolog even consum
audienc growth perspect look outsid life scienc tool
coverag find compani similar profil chart weve
analyz six large-cap internet name make interest set peer given size
growth trajectori interestingli trade doubl sale
multipl internet compar compani quadrupl multipl
look ev sale growth
thomson one consensu data compani
note price
note price
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
